27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Consistent with previous research, transfer gains from the OMT condition to an untrained VM task suggest that olfaction may contribute to a‐modal representations of memory. 3 key findings →
Participants: 53 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the 747 studies identified, 6 studies fulfilled the eligibility criterion for this review. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Emotion scores for fear and surprise were significantly higher for the AD group than for the MCI group during dual tasks (p=0.016), while emotion scores for joy were significantly higher for the MCI group than for the AD group during creative activities (p=0.012). 4 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma Aβ levels and regional WMH burden are associated with glymphatic dysfunction as indicated by reduced ALPS. 3 key findings →
Participants: 216 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Socioeconomic disadvantage is recognized as a risk factor for cognitive decline, yet its associated neural pathways remain unclear. 5 key findings →
Participants: 822 Evidence: low
Full summary, score breakdown and related studies → Original source
Increased levels of inflammatory markers were not associated with faster progression as measured by the annual change on the CDR-SB or MMSE score. 2 key findings →
Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We performed a retrospective analysis of the patients assessed at our memory unit for whom Alzheimer disease (AD) cerebrospinal fluid biomarker results were available. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is a multifactorial, age-related neurological disease characterized by complex pathophysiological dynamics taking place at multiple biological levels, including molecular, genetic, epigenetic, cellular and large-scale brain networks. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Synaptic disruption is an early pathological sign of the neurodegeneration of Dementia of the Alzheimer's type (DAT). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Individualized multidomain interventions may improve cognition and reduce AD/cardiovascular risk scores in patients at-risk for AD dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The present study explores the role of cognitive reserve, executive functions, and working memory (WM) span, as factors that might explain training outcomes in cognitive status. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Participants included 10 physiatrists, 6 OTs, and 11 patients with mild cognitive impairment and mild dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
β-Amyloid (Aβ) plaque deposition and neurodegeneration within temporoparietal and hippocampal regions may indicate increased risk of Alzheimer's disease (AD). 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI), an identified prodromal stage of Alzheimer's Disease (AD), often evades detection in the early stages of the condition, when existing diagnostic methods are employed in the clinical setting. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Due to the lack of pharmacological treatment for dementia, timely detection of subjects at risk can be of seminal importance for preemptive rehabilitation interventions. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent failures of potential novel therapeutics for Alzheimer's disease (AD) have prompted a drive towards clinical studies in prodromal or preclinical states. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
One of the major neuropathological findings in the brains of individuals with Alzheimer's disease (AD) is a loss of synaptic contacts in both the neocortex and hippocampus. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Animal models of human diseases that accurately recapitulate clinical pathology are indispensable for understanding molecular mechanisms and advancing preclinical studies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
[ 18 F]PI-2620 was selected for clinical validation. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In the A4 study, solanezumab did not reduce the decline in cognition or function and had no effect on brain amyloid burden. 1 key finding →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source
Several flavonoids have been recognized as nutraceuticals, and myricetin is a good example. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mild cognitive impairment (MCI) is often considered to be a transitional stage between normal aging and dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Using subset of optimal features in SVM, we classified MCI-C from MCI-NC with an accuracy, sensitivity, specificity, and the area under the receiver operating characteristic (ROC) curve of 91.4%, 83.24%, 90.1%, and 0.95, respectively. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Brain network alterations in patients with Alzheimer's disease (AD) has been the subject of much investigation, but the biological mechanisms underlying these alterations remain poorly understood. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is characterised by a long preclinical phase. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 2,141 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →